NEW YORK – Neurodegenerative disease diagnostic company T-NeuroDx announced on Thursday that it is collaborating with Danaher subsidiary Beckman Coulter Life Sciences to assess a next-generation blood test for early detection of Alzheimer's disease.
The test detects T-NeuroDx's proprietary biomarker, an abnormal population of self-reactive T cells. The collaboration will combine T-NeuroDx's research in Alzheimer's diagnostics with Beckman Coulter's flow cytometry products and is intended to demonstrate the potential of the test to detect an initiating event before dysregulated beta-amyloid and tau, the current standard of care for Alzheimer's biomarker-based diagnostics, are detectable, the company said in a statement.
"This collaboration represents a significant step forward in our mission to advance early detection of Alzheimer’s disease," T-NeuroDx CEO Kristina Trujillo said in a statement. "By combining our novel biomarker discovery with the proprietary flow cytometry technology from Beckman Coulter Life Sciences, we're working to develop a more accessible and scalable blood-based test that could transform how we diagnose Alzheimer's disease in its earliest stages."
Albuquerque, New Mexico-based T-NeuroDx is an early-stage diagnostics company developing novel, blood-based biomarkers to enable early detection of Alzheimer's and other neurodegenerative diseases.
"The neuroimmunology field has long been riddled with complexities which stood in the way of significant advancements, and the introduction of streamlined flow cytometry assays could offer promising new potential for translational research," Jean-Marc Busnel, senior staff research scientist at Beckman Coulter Life Sciences, added. "As the benefits of flow cytometry are incorporated into more research and diagnostic disciplines, we look forward to supporting laboratories in their journey and together help to advance human health."
Financial and other details of the agreement were not disclosed.